A 47-year old Middle Eastern woman presented to the emergency department with a 1-day history of dizziness and feeling generally unwell and rectal bleeding of several weeks' duration. Her history was notable for rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy, followed by low anterior resection with ileostomy and adjuvant chemotherapy, which was completed 5 months before presentation. One month before presentation, she experienced rectal bleeding, and recurrent adenocarcinoma was diagnosed. Recommendation from her oncologist was to commence salvage chemotherapy. However, thrombocytopenia was noted on her prechemotherapy blood tests, prompting the decision to defer chemotherapy and refer her to the emergency department for evaluation. She had no other relevant medical history, was a lifelong nonsmoker, did not drink alcohol, and was not taking any medications regularly.
A 47-year old Middle Eastern woman presented to the emergency department with a 1-day history of dizziness and feeling generally unwell and rectal bleeding of several weeks' duration. Her history was notable for rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy, followed by low anterior resection with ileostomy and adjuvant chemotherapy, which was completed 5 months before presentation. One month before presentation, she experienced rectal bleeding, and recurrent adenocarcinoma was diagnosed. Recommendation from her oncologist was to commence salvage chemotherapy. However, thrombocytopenia was noted on her prechemotherapy blood tests, prompting the decision to defer chemotherapy and refer her to the emergency department for evaluation. She had no other relevant medical history, was a lifelong nonsmoker, did not drink alcohol, and was not taking any medications regularly.
On presentation, testing of her vital signs revealed the following: temperature, 37.8 C; blood pressure, 84/55 mm Hg; heart rate, 125 beats/min; respiratory rate, 18 breaths/ min; and 95% oxygen saturation while breathing room air. She appeared ill, but her extremities were warm, and capillary refill time was less than 2 seconds; the remainder of the examination was notable for a healthyappearing ileostomy and mild tenderness in the lower quadrants of the abdomen. She had no rashes or petechiae.
Initial laboratory evaluation yielded the following results (reference ranges provided parenthetically): hemoglobin, 7.7 g/dL (12-15.5 g/dL); mean corpuscular volume, 84.1 fL (81.6-98.T3 fL); leukocytes, 18.5 Â /L, respectively, and creatinine at 0.6 mg/dL. Computed tomography of the abdomen and pelvis revealed a presacral mass, consistent with local tumor recurrence.
The patient was treated with intravenous fluids, and shortly after admission, blood and urine cultures were positive for Escherichia coli; broad-spectrum antibiotics were initiated. The first step in the evaluation of thrombocytopenia in an acutely ill patient is the exclusion of hematologic emergencies, such as disseminated intravascular coagulation (DIC) and thrombotic thrombocytopenic purpura (TTP). To this end, evaluation of the peripheral blood smear is the most important initial investigation, as it can assess all 3 hematopoietic lineages.
1 Pseudothrombocytopenia (platelet clumping) can be ruled out with a peripheral blood smear, and morphologic abnormalities in red (eg, schistocytes) and white (eg, leukemic cells, atypical lymphocytes) blood cells can be identified. A bone marrow examination is useful to evaluate cytopenia because it can identify evidence of reduced hematopoiesis, destruction of cell lines, and infiltrative processes. However, it should be performed if results of other less invasive tests are inconclusive or if a suspected hematologic diagnosis requires pathologic confirmation. Measurement of platelet factor 4 antibodies is used in the diagnosis of heparin-induced thrombocytopenia, but it is not appropriate in the evaluation of thrombocytopenia in a patient with no history of recent exposure to heparin. Peripheral blood flow cytometry can be helpful in diagnosing paroxysmal nocturnal hemoglobinuria and evaluation for the presence of clonal hematopoietic proliferation, but these tests would be premature at this point. Although cellbound platelet antibodies can be detected in patients who have idiopathic thrombocytopenic purpura, they are neither sensitive nor specific for this condition. In addition, our patient has bicytopenia, not isolated thrombocytopenia.
A peripheral blood smear was performed and revealed scant schistocytes with no evidence of platelet clumping. Further laboratory testing was notable for the following results: reticulocytes, 107 Â Iron deficiency typically leads to a microcytic anemia, which is not seen in this patient. Additionally, the ferritin level is high, which argues against iron deficiency, although it may be falsely elevated in the setting of sepsis (it is an acute-phase reactant). Myelodysplastic syndrome is characterized by ineffective hematopoiesis leading to a macrocytic or normocytic anemia in addition to other cytopenias, and it can develop in patients who have had chemotherapy. However, this condition requires identification of dysplastic features on bone marrow biopsy and cannot yet be diagnosed in this patient. The presence of schistocytes indicates fragmentation of red blood cells and raises suspicion for microangiopathic hemolytic anemia (MAHA).
2 Moreover, the elevated LDH level, low haptoglobin level, and indirect hyperbilirubinemia in this patient provides supporting evidence for hemolysis. Thalassemia (particularly a-thalassemia) is common in Middle Eastern individuals but leads to a microcytic, rather than normocytic, anemia. Although acute blood loss from the gastrointestinal tract could be contributing to this patient's anemia, it does not explain the presence of schistocytes, the indirect hyperbilirubinemia, or the low haptoglobin level.
Additional testing to evaluate for a bleeding diathesis revealed the following notable results: prothrombin time (PT), 34 seconds (9.4-12.5 seconds); active partial thromboplastin time (APTT), 52 seconds (25-37 seconds); fibrinogen, 415 mg/dL (200-393 mg/dL); D-dimer, 1830 ng/mL fibrinogen-equivalent units (<500 ng/mL fibrinogen-equivalent units); von Willebrand factor (VWF) antigen, 309% (55%-200%); and VWF activity, 286% (55%-200%). The PT and APTT were 12.7 seconds and 32 seconds, respectively, after a mixing study was performed. Testing of individual factor activity revealed the following: factor II, 46% (75%-145%); factor V, 63% (70%-165%); factor VII, 18% (65%-180%); factor VIII, 166% (55%-200%); factor IX, 49% (65%-140%); and factor X, 33% (70%-150%). Hemophilia A is an X chromosomee linked recessive disease caused by inherited deficiency of factor VIII, with female carriers usually being asymptomatic or exhibiting a mild bleeding phenotype. The disease is characterized by a prolonged APTT and a normal PT (both are prolonged in this patient), as well as an isolated reduction in factor VIII activity, which is not seen in this patient. Hemophilia B is also characterized by a prolonged APTT and a normal PT, with an isolated reduction in factor IX activity but normal levels of other coagulation factors. von Willebrand disease is the most common inherited bleeding disorder and is caused by deficiency of VWF, which facilitates clot formation by forming a bridge between platelets and the endothelium. Although the APTT may be prolonged in VWD (as VWF protects factor VIII against proteolysis), the patient does not have a low VWF antigen or activity level. Factor VII deficiency is an extremely rare condition and may be either inherited or secondary to malignancy or sepsis; it presents with an elevated PT, normal APTT, and reduced factor VII activity. Given that the patient has a prolonged PT and APTT, isolated factor VII deficiency is not a possibility. Vitamin K is a necessary cofactor for several carboxylase enzymes in hepatocytes, which are needed for the activation of factors II, VII, IX, and X. Vitamin K deficiency therefore leads to reduced activity of these factors, producing prolonged PT and APTT (owing to interference with both the extrinsic and common coagulation cascades), which normalize on mixing studies, as seen in this patient. Although vitamin K deficiency is typically seen in malabsorptive states, cancer-related malnutrition can lead to nutritional deficiency and is likely in this patient. The mild reduction in factor V activity in this patient is not explained by vitamin K deficiency and likely is due to synthetic liver dysfunction, which is supported by the presence of hypoalbuminemia in this case.
The patient was given 5 mg of oral vitamin K for 3 days, with resultant reduction in PT and APTT. Additional evaluation for thrombocytopenia and hemolytic anemia revealed an ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13) activity of less than 5%, with the presence of an inhibitor. A diagnosis of decompensated DIC is supported by laboratory features of consumptive coagulopathy (prolonged PT and APTT, thrombocytopenia, low fibrinogen level, elevated D-dimer, and features of MAHA) in the appropriate clinical (ie, bleeding or thrombosis) and historical (eg, presence of sepsis and/or malignancy) context. In this case, the absence of hypofibrinogenemia argues against decompensated DIC. Further, although severe thrombocytopenia can be seen in DIC, it is typically mild to moderate in this condition. 3 Although the prolongation of PT and APTT in this case raises the possibility of DIC, vitamin K supplementation would not correct these parameters in DIC, which are therefore more likely explained by vitamin K deficiency. The coexistence of MAHA, thrombocytopenia, and organ injury (renal failure in this patient) are hallmarks of a thrombotic microangiopathy (TMA), which comprises a series of disorders including TTP, HUS, drug-mediated TMAs, cancer-related TMA, and rare hereditary disorders. 4 Thrombotic thrombocytopenic purpura is caused by a hereditary or acquired deficiency of ADAMTS13, a protease that cleaves VWF multimers from vascular endothelial cells. The very low ADAMTS13 activity in our patient indicates severe deficiency, thereby confirming the diagnosis of TTP. Hemolytic uremic syndrome is a diagnostic consideration, as it is characterized by MAHA, thrombocytopenia, and acute kidney injury, all of which are seen in this patient. However, hemolytic uremic syndrome is less common than TTP, is more frequently seen in children, and is not associated with severe deficiency of ADAMTS13 (or an antibody to ADAMTS13). The ST-HUS is usually mediated by Shiga toxineproducing E coli (commonly the O157:H7 strain), and although our patient had an E coli bacteremia, she did not report a history of diarrhea or abdominal pain, which are key components of the presentation of ST-HUS. 4 Microangiopathic hemolytic anemia and thrombocytopenia may be seen in systemic lupus erythematosus, and although its manifestations are protean, the acute presentation, lack of autoimmune disease history, and absence of multisystem involvement in this case make it very unlikely. Paroxysmal nocturnal hemoglobinuria causes a direct antiglobulin testenegative hemolytic anemia and can cause other cytopenias. However, it usually is not associated with schistocytes, and other characteristic features of this condition, such as hemoglobinuria, venous thrombosis, and smooth muscle dystonia, are absent in this case. 5 With a confirmed diagnosis of TTP, input from the hematology department was sought to provide recommendations for treatment. Although generally not thought to be harmful in TTP, platelet transfusion plays no accepted role in its management. 6 However, it may be used in the supportive care of patients with TTP who have either a high risk of bleeding or active hemorrhage. Intravenous immunoglobulin has a role in the management of immune-mediated cytopenia, but the evidence for its role in the treatment of TTP is limited to case reports, and no evidence for its efficacy has been found. Historically, splenectomy was used in the management of TTP because it may eliminate the lymphocyte clone producing the ADAMTS13 inhibitor in some patients. However, a major surgical procedure in an acutely ill patient has substantial risk, and its role is now limited largely to an option in managing patients with multiple relapses of TTP. Daily PLEX is the mainstay of therapy for TTP and should be commenced immediately in any patient who has a presumptive diagnosis of TTP, even while awaiting results of confirmatory diagnostic testing (ADAMTS13 activity). 7 This therapy is believed to provide benefit by replacing ADAMTS13 and/or removing the autoantibodies that are inhibiting its activity in patients with acquired TTP, as in this patient. Glucocorticoids are routinely added to PLEX in cases such as ours in which an inhibitor is present, as they may suppress autoantibody production (and are therefore not needed in congenital TTP). The role of rituximab, an anti-CD20 agent that depletes B lymphocytes, in addition to that of glucocorticoids and PLEX, is not well characterized. Expert consensus recommends its consideration in the first-line treatment of acquired TTP, but it is more commonly used in patients whose TTP is refractory to PLEX and glucocorticoids. 8 The rationale of performing PLEX twice daily (as opposed to once daily) is that a higher volume of plasma can be infused, which may provide a greater benefit. However, evidence to support this approach is limited, and given the doubling of time and resources required, it is rarely used in first-line therapy and only infrequently in TTP that is refractory to daily PLEX. 9 A regimen of prednisone, 60 mg daily, and daily PLEX was initiated. After 9 days, the patient's platelet count had stabilized to approximately 150 Â 10 9 /L, and her hemolytic parameters and ADAMTS13 activity had normalized, at which point PLEX was discontinued. She was discharged home with a slow taper of prednisone and remained well, with a stable platelet count at her outpatient followup 2 weeks later.
DISCUSSION
Thrombotic thrombocytopenic purpura is a disorder that is fatal without prompt and appropriate treatment and should be recognized as a medical emergency. Although it is a rare disease with an incidence of 3 per 1,000,000 adults per year, 10 the identification of both MAHA and thrombocytopenia should alert the clinician and prompt further diagnostic testing as outlined in this case.
The disorder is caused by a congenital or acquired deficiency of ADAMTS13, with the former being extremely rare. In the case of the latter, an autoantibody inhibits the activity of ADAMTS13, the deficiency of which leads to accumulation of ultralarge VWF multimers and the consequent development of platelet thrombi in small vessels. Classicly, TTP has been described as the pentad of thrombocytopenia, MAHA, fever, neurologic abnormalities, and renal failure, but this presentation was reported to occur in only 5% of cases in a large single-center series. 7 Gastrointestinal tract symptoms (such as nausea, vomiting, and diarrhea) and neurologic abnormalities (such as seizure or stroke) are common, with weakness and bleeding manifestations being noted in more than 50% of patients. 7 The diagnostic approach to TTP should include the following: testing to confirm the presence of MAHA (by means of a peripheral blood smear, LDH, haptoglobin, bilirubin, and direct antiglobulin tests); assessment for possible complications of the condition (such as renal impairment); attempts to rule out TTP mimics such as DIC (via measurement of PT, APTT, and fibrinogen); and confirmation of the diagnosis (by documentation of reduced ADAMTS13 activity and/or the presence of an inhibitor). However, a crucial point is that the confirmation of reduced ADAMTS13 activity is not required to make the diagnosis and should not delay treatment. 11 The mainstay of management of acquired TTP is daily PLEX and glucocorticoids (oral prednisone at a dose of 1 mg/kg per day or intravenous methylprednisone at 125 mg up to 4 times daily). The addition of rituximab for first-line therapy is controversial and generally not utilized in routine practice. A recent randomized phase 2 trial found that the addition of caplacizumab, a monoclonal antibody that inhibits the interaction between VWF and platelets, could lead to faster resolution of an acute episode of acquired TTP. 12 Assessment of treatment response is guided by monitoring the platelet count, with an increase expected after the second or third PLEX treatment and normalization at the end of 7 days. 7 PLEX is typically discontinued after normalization of the platelet count (ie, >150 Â 10 9 /L) has been seen on 2 consecutive days, although it may also be weaned more slowly with increasing duration between exchanges. Corticosteroid therapy is maintained at full dose for a further 5 to 7 days before a slow taper over 2 to 3 weeks is employed, assuming the platelet count remains normal. 7 Once a remission is achieved, regular blood monitoring is not required, although the platelet count should be checked to assess for relapse if any signs of illness or infection appear.
CONCLUSION
This case highlights the importance of considering TTP in the differential diagnosis of hemolytic anemia and thrombocytopenia. Although the presentation may be nonspecific, the diagnostic evaluation should proceed in a systematic manner to identify the key features of TTP, and treatment, in the form of PLEX and corticosteroids, must not be delayed while awaiting confirmation of the diagnosis.
